Literature DB >> 3356905

In vivo evaluation of radiolabelled antibodies with antigen-coated polymer particles in diffusion chambers.

J G Fjeld1, H B Benestad, T Stigbrand, K Nustad.   

Abstract

A method for the evaluation of in vivo immunolocalization of labelled monoclonal antibodies (MoAb) is presented. The technique is an alternative to the nude mouse xenograft system. The antigen reservoir is an intraperitoneal diffusion chamber (DC) filled with a suspension of antigen-coated polymer particles. Intravenously injected 125I-labelled MoAb are allowed to specifically bind to this artificial abdominal 'tumour', which can be removed and measured for radioactivity after animal killing. The model can be used as a preclinical in vivo method for the evaluation of labelled MoAbs prepared for immunodiagnostics or therapy. The DC system permits the amounts of both antibody and antigen to be controlled and antibody access to the antigen within the DC is presumably the same in every animal. The model permits a systematic comparison of different antibodies and antibody fragments, labels and labelling procedures, as well as routes of administration in immunocompetent animals.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3356905     DOI: 10.1016/0022-1759(88)90435-8

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Syngeneic anti-idiotypic antibodies eliminate excess radiolabeled idiotypes at experimental radioimmunolocalization.

Authors:  A Ullén; K Riklund Ahlström; R Makiya; T Stigbrand
Journal:  Cell Biophys       Date:  1995-08

2.  Radioimmunotargeting of human tumour cells in immunocompetent animals.

Authors:  J G Fjeld; O S Bruland; H B Benestad; L Schjerven; T Stigbrand; K Nustad
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

3.  In vivo measurement of the association constant of a radio-labelled monoclonal antibody in experimental immunotargeting.

Authors:  J G Fjeld; H B Benestad; T Stigbrand; K Nustad
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.